{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:08:09Z","timestamp":1789502889234,"version":"build-2803163510"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.semarthrit.2025.152667","type":"journal-article","created":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T11:20:43Z","timestamp":1740223243000},"page":"152667","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["The prognostic power of anti-topoisomerase I and anti-centromere antibodies in systemic sclerosis - A systematic review of the literature"],"prefix":"10.1016","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2437-6016","authenticated-orcid":false,"given":"E.M.","family":"Hoekstra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.I.E.","family":"Liem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Boonstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.M.","family":"Fehres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.W.","family":"Schoones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.W.J.","family":"Huizinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.K.","family":"de Vries-Bouwstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10103","key":"10.1016\/j.semarthrit.2025.152667_bib0001","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2025.152667_bib0002","doi-asserted-by":"crossref","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152667_bib0003","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2005.03.005","article-title":"Autoantibodies in systemic sclerosis","volume":"35","author":"Steen","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2025.152667_bib0004","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fimmu.2015.00167","article-title":"Autoantibodies in systemic sclerosis: unanswered questions","volume":"6","author":"Kayser","year":"2015","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.semarthrit.2025.152667_bib0005","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1002\/art.24038","article-title":"Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis","volume":"58","author":"Koenig","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152667_bib0006","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152667_bib0007","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nrrheum.2009.238","article-title":"OPINION autoantibodies as predictive tools in systemic sclerosis","volume":"6","author":"Nihtyanova","year":"2010","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152667_bib0008","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.berh.2009.12.002","article-title":"Evidence-based management of rapidly progressing systemic sclerosis","volume":"24","author":"Khanna","year":"2010","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152667_bib0009","first-page":"581","article-title":"Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee","volume":"23","year":"1980","journal-title":"Arthritis Rheum"},{"issue":"7306","key":"10.1016\/j.semarthrit.2025.152667_bib0010","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/bmj.323.7306.224","article-title":"Systematic reviews of evaluations of prognostic variables","volume":"323","author":"Altman","year":"2001","journal-title":"Bmj"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152667_bib0011","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.semarthrit.2025.152667_bib0012","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/art.24734","article-title":"Clinical and genetic factors predictive of mortality in early systemic sclerosis","volume":"61","author":"Assassi","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152667_bib0013","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1002\/art.38381","article-title":"Derivation and validation of a prediction rule for two-year mortality in early diffuse cutaneous systemic sclerosis","volume":"66","author":"Domsic","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152667_bib0014","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/art.39490","article-title":"Derivation and external validation of a prediction rule for five-year mortality in patients with early diffuse cutaneous systemic sclerosis","volume":"68","author":"Domsic","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152667_bib0015","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00005792-200203000-00004","article-title":"Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients","volume":"81","author":"Ferri","year":"2002","journal-title":"Medicine"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152667_bib0016","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/art.40027","article-title":"Early mortality in a multinational systemic sclerosis inception cohort","volume":"69","author":"Hao","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152667_bib0017","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1136\/annrheumdis-2016-210503","article-title":"Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS)","volume":"76","author":"Herrick","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152667_bib0018","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/rheumatology\/keg170","article-title":"The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis","volume":"42","author":"Hesselstrand","year":"2003","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152667_bib0019","first-page":"2454","article-title":"Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis","volume":"28","author":"Jacobsen","year":"2001","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152667_bib0020","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/art.1780370111","article-title":"Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis","volume":"37","author":"Kuwana","year":"1994","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152667_bib0021","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1007\/BF02238937","article-title":"Predictors of survival in 171 patients with systemic sclerosis (scleroderma)","volume":"16","author":"Nagy","year":"1997","journal-title":"Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152667_bib0022","doi-asserted-by":"crossref","first-page":"588","DOI":"10.3109\/14397595.2015.1115455","article-title":"Incidence and predictors of interstitial lung disease (ILD) in Thai patients with early systemic sclerosis: inception cohort study","volume":"26","author":"Wangkaew","year":"2016","journal-title":"Mod Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152667_bib0023","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1183\/09031936.00060209","article-title":"Prognostic factors for lung function in systemic sclerosis: prospective study of 105 cases","volume":"35","author":"Gilson","year":"2010","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152667_bib0024","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/acr.24873","article-title":"Damage trajectories in systemic sclerosis using group-based trajectory modeling","volume":"75","author":"Barbacki","year":"2023","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2025.152667_bib0025","article-title":"Sex influence on outcomes of patients with systemic sclerosis-associated interstitial lung disease: an EUSTAR database analysis","author":"Campochiaro","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152667_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102452","article-title":"Outcomes of limited cutaneous systemic sclerosis patients: results on more than 12,000 patients from the EUSTAR database","volume":"19","author":"Frantz","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"Si","key":"10.1016\/j.semarthrit.2025.152667_bib0027","doi-asserted-by":"crossref","first-page":"Si91","DOI":"10.1093\/rheumatology\/keac405","article-title":"Use of platelet inhibitors for digital ulcers related to systemic sclerosis: EUSTAR study on derivation and validation of the DU-VASC model","volume":"62","author":"Garaiman","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152667_bib0028","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/2397198319869564","article-title":"Prediction of organ involvement and survival in systemic sclerosis patients in the first 5years from diagnosis","volume":"5","author":"van den Hombergh","year":"2020","journal-title":"J Scleroderma Relat Disord"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152667_bib0029","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/rmdopen-2022-002673","article-title":"Latent trajectory modelling of pulmonary artery pressure in systemic sclerosis: a retrospective cohort study","volume":"8","author":"Kida","year":"2022","journal-title":"Rmd Open"},{"issue":"17","key":"10.1016\/j.semarthrit.2025.152667_bib0030","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11175013","article-title":"Anemia is an indicator for worse organ damage trajectories in patients with systemic sclerosis: a retrospective study","volume":"11","author":"Li","year":"2022","journal-title":"J Clin Med"},{"issue":"10","key":"10.1016\/j.semarthrit.2025.152667_bib0031","doi-asserted-by":"crossref","first-page":"e699","DOI":"10.1016\/S2665-9913(22)00224-7","article-title":"Sex-specific risk of anti-topoisomerase antibodies on mortality and disease severity in systemic sclerosis: 10-year analysis of the Leiden CCISS and EUSTAR cohorts","volume":"4","author":"Liem","year":"2022","journal-title":"Lancet Rheumatol"},{"issue":"10","key":"10.1016\/j.semarthrit.2025.152667_bib0032","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1093\/rheumatology\/keac118","article-title":"Gastrointestinal symptom severity and progression in systemic sclerosis","volume":"61","author":"van Leeuwen","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152667_bib0033","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/art.41153","article-title":"Using autoantibodies and cutaneous subset to develop outcome-based disease classification in systemic sclerosis","volume":"72","author":"Nihtyanova","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152667_bib0034","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/art.42349","article-title":"Dynamic prediction of pulmonary hypertension in systemic sclerosis using landmark analysis","volume":"75","author":"Nihtyanova","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2025.152667_bib0035","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.3899\/jrheum.210533","article-title":"Esophageal dilation and other clinical factors associated with pulmonary function decline in patients with systemic sclerosis","volume":"48","author":"Showalter","year":"2021","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152667_bib0036","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.semarthrit.2019.11.005","article-title":"Mortality and hospitalization outcomes of interstitial lung disease and pulmonary hypertension in the Singapore systemic sclerosis cohort","volume":"50","author":"Noviani","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152667_bib0037","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13075-019-1867-1","article-title":"Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature","volume":"21","author":"Pokeerbux","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.1016\/j.semarthrit.2025.152667_bib0038","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1093\/rheumatology\/keac188","article-title":"Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort","volume":"61","author":"Zanatta","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152667_bib0039","first-page":"1573","article-title":"Jr. Criteria for the classification of early systemic sclerosis","volume":"28","author":"LeRoy","year":"2001","journal-title":"J Rheumatol"},{"issue":"10","key":"10.1016\/j.semarthrit.2025.152667_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103167","article-title":"Standardized incidence ratios and risk factors for cancer in patients with systemic sclerosis: data from the Spanish Scleroderma Registry (RESCLE)","volume":"21","author":"Carbonell","year":"2022","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152667_bib0041","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1186\/s13075-021-02672-y","article-title":"Sine scleroderma, limited cutaneous, and diffused cutaneous systemic sclerosis survival and predictors of mortality","volume":"23","author":"De Almeida Chaves","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152667_bib0042","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.semarthrit.2020.02.015","article-title":"Evolution of high-resolution CT-scan in systemic sclerosis-associated interstitial lung disease: description and prognosis factors","volume":"50","author":"Forestier","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152667_bib0043","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00296-016-3475-6","article-title":"Survival and causes of death in systemic sclerosis patients: a single center registry report from Iran","volume":"36","author":"Poormoghim","year":"2016","journal-title":"Rheumatol Int"},{"issue":"10","key":"10.1016\/j.semarthrit.2025.152667_bib0044","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s10067-013-2289-0","article-title":"Mortality in systemic sclerosis-a single centre study from the UK","volume":"32","author":"Strickland","year":"2013","journal-title":"Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152667_bib0045","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1183\/09031936.00004711","article-title":"Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis","volume":"38","author":"Tiev","year":"2011","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152667_bib0046","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/art.38390","article-title":"Prediction of pulmonary complications and long-term survival in systemic sclerosis","volume":"66","author":"Nihtyanova","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152667_bib0047","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.semarthrit.2015.04.009","article-title":"Thinking outside the box\u2013the associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect","volume":"45","author":"Srivastava","year":"2015","journal-title":"Semin Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152667_bib0048","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/rheumatology\/kew298","article-title":"Survival and organ involvement in patients with limited cutaneous systemic sclerosis and anti-topoisomerase-I antibodies: determined by skin subtype or auto-antibody subtype? A long-term follow-up study","volume":"55","author":"Kranenburg","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2025.152667_bib0049","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ijcard.2016.08.246","article-title":"N-terminal pro-brain natriuretic peptide is a strong predictor of mortality in systemic sclerosis","volume":"223","author":"Allanore","year":"2016","journal-title":"Int J Cardiol"},{"issue":"12","key":"10.1016\/j.semarthrit.2025.152667_bib0050","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1093\/rheumatology\/kew313","article-title":"Calcinosis is associated with digital ischaemia in systemic sclerosis-a longitudinal study","volume":"55","author":"Baron","year":"2016","journal-title":"Rheumatology (United Kingdom)"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152667_bib0051","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/art.42054","article-title":"Diastolic dysfunction in systemic sclerosis: risk factors and impact on mortality","volume":"74","author":"Hinze","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152667_bib0052","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1136\/annrheumdis-2012-202849","article-title":"The degree of skin involvement identifies distinct lung disease outcomes and survival in systemic sclerosis","volume":"73","author":"Cottrell","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152667_bib0053","article-title":"Risk factors for lung function decline in systemic sclerosis-associated interstitial lung disease in a large single-center cohort","author":"Ramahi","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152667_bib0054","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3899\/jrheum.180582","article-title":"Scleroderma renal crisis: risk factors for an increasingly rare organ complication","volume":"47","author":"Moinzadeh","year":"2020","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152667_bib0055","article-title":"Risk-of-bias VISualization (robvis): an R package and shiny web app for visualizing risk-of-bias assessments","author":"McGuinness","year":"2020","journal-title":"Res Synth Methods"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152667_bib0056","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/acr.22121","article-title":"Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in Scleroderma registry","volume":"66","author":"Chung","year":"2014","journal-title":"Arthritis Care Res"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152667_bib0057","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/00005792-200203000-00005","article-title":"Predicting mortality in systemic sclerosis - analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival","volume":"81","author":"Scussel-Lonzetti","year":"2002","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152667_bib0058","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/art.1780310207","article-title":"Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis","volume":"31","author":"Steen","year":"1988","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152667_bib0059","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.semarthrit.2018.02.005","article-title":"Does nailfold capillaroscopy help predict future outcomes in systemic sclerosis? A systematic literature review","volume":"48","author":"Paxton","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152667_bib0060","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/rheumatology\/kez005","article-title":"Prognostic properties of anti-topoisomerase antibodies in patients identified by the ACR\/EULAR 2013 systemic sclerosis criteria","volume":"58","author":"Boonstra","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.semarthrit.2025.152667_bib0061","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/art.41814","article-title":"Anticentromere antibody levels and isotypes and the development of systemic sclerosis","volume":"73","author":"van Leeuwen","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152667_bib0062","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1002\/art.41403","article-title":"Association of Anti-topoisomerase I antibodies of the IgM isotype with disease progression in Anti-topoisomerase I-positive systemic sclerosis","volume":"72","author":"Boonstra","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152667_bib0063","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002827","article-title":"Progression from suspected to definite systemic sclerosis and the role of anti-topoisomerase I antibodies","volume":"9","author":"Liem","year":"2023","journal-title":"RMD Open"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225000381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225000381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T01:48:55Z","timestamp":1767750535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017225000381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":63,"alternative-id":["S0049017225000381"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152667","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The prognostic power of anti-topoisomerase I and anti-centromere antibodies in systemic sclerosis - A systematic review of the literature","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152667","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152667"}}